RP
Insider
RA Capital Nexus Fund II, L.P.
DirectorRA Capital Nexus Fund II, L.P. (Director) filed 1 Form 4 report as a reporting entity in the past 24 months (1 purchase, 0 sales), most often in Werewolf Therapeutics, Inc. (HOWL). Across 1 priced purchase filing, the average 21-session return was +58.7% from execution and +26.5% from disclosure (delay-adjusted; derived). The largest single filing was $435K of HOWL (483,452 sh across 2 lots, as filed), executed May 12 2025.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+58.7%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+26.5%
same 1 filings, from disclosure
Filings, ttm
1
1 buys · 0 sells
Median delay
2d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$435K
shares × price, as filed
Last traded
May 14 2025
Filed May 14 2025
Median ADV $290K across their filed names
Open performance→Volume by month
Buys $435K
Sells $0
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
1 filing
Sector per market data · by filing · past 24 months
Most traded names
HOWLRecent filings
HOWLPURCHASE
Werewolf Therapeutics, Inc.
View filing →
$435K483,452 sh across 2 lots
Exec May 12 2025
Filed May 14 2025 · 5:30 PM ET